论文部分内容阅读
目的通过不同剂量促红细胞生成素(EPO)治疗老年化疗后肿瘤相关性贫血的疗效,及血栓形成危险性的比较。方法 60例恶性实体瘤化疗后贫血患者,根据EPO剂量不同分为常规治疗组(35例)和加大剂量治疗组(25例)。常规治疗组给予EPO1000 IU,加大剂量治疗组给予EPO20000 IU。比较两组治疗前后血红蛋白(Hb)及凝血指标变化情况。结果两组治疗后Hb、红细胞压积(HCT)均升高,与治疗前比较差异有统计学意义(P<0.05),其余5项凝血指标治疗前后比较差异无统计学意义(P>0.05)。常规治疗组治疗前后Hb差值为(3.80±11.88)g/L,加大剂量治疗组为(9.64±8.04)g/L,比较差异有统计学意义(P<0.05),其余6项凝血指标比较均差异无统计学意义(P>0.05)。结论治疗老年肿瘤化疗相关性贫血EPO两组剂量皆有效,增加剂量时疗效增加,未增加血栓危险性。
Objective To compare the efficacy of different doses of erythropoietin (EPO) in the treatment of cancer-associated anemia after geriatric chemotherapy and the risk of thrombosis. Methods Sixty anemia patients with malignant solid tumor after chemotherapy were divided into routine treatment group (n = 35) and increased dose treatment group (n = 25) according to the dose of EPO. The conventional treatment group was given EPO 1000 IU, and the enlarged dose treatment group was given EPO 20000 IU. The changes of hemoglobin (Hb) and coagulation index before and after treatment were compared between the two groups. Results The Hb and hematocrit (HCT) of both groups were increased after treatment, with statistical significance (P <0.05) before and after treatment. There was no significant difference between the other five coagulation indexes before and after treatment (P> 0.05) . The difference of Hb before and after treatment in the conventional treatment group was (3.80 ± 11.88) g / L and (9.64 ± 8.04) g / L in the large dose treatment group, with statistical significance (P <0.05) There was no significant difference between the two groups (P> 0.05). Conclusion The treatment of elderly patients with chemotherapy-related anemia EPO dose of two groups are effective, increasing the dose increased efficacy, did not increase the risk of thrombosis.